CytRx Corporation (NASDAQ:CYTR) Receiving Somewhat Favorable Media Coverage, Accern Reports
Headlines about CytRx Corporation (NASDAQ:CYTR) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytRx Corporation earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.2359323584353 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- CytRx New Drug Development Agreement Brings Cash and Experience (finance.yahoo.com)
- Calling all Bargain Hunters: Stock Update on CytRx Corporation (NASDAQ:CYTR) – FLBC News (flbcnews.com)
- Still Listen to?: CytRx Corporation (CYTR) dropped with negative flow of -23.17% during recent week – Voice Of Analysts (analystsbuzz.com)
- CytRx Corporation (CYTR) is at $0.63 per share and Depomed, Inc. (DEPO) is listed at $9.47 – Stocks Gallery (stocksgallery.com)
Shares of CytRx Corporation (CYTR) traded down 0.65% during midday trading on Monday, hitting $0.61. The company had a trading volume of 989,484 shares. CytRx Corporation has a 12 month low of $0.36 and a 12 month high of $1.00. The company’s market capitalization is $101.08 million. The company has a 50-day moving average of $0.65 and a 200-day moving average of $0.53.
A number of brokerages recently issued reports on CYTR. ValuEngine raised CytRx Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of CytRx Corporation in a research note on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $2.50.
CytRx Corporation Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Stock Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related stocks with our FREE daily email newsletter.